Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

by admin | Feb 12, 2026 | Health

Spread the love

New England Journal of Medicine, Volume 394, Issue 7, Page 635-646, February 12, 2026.

← Mucormycosis Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents →

Written By

Written by Albert Pham, News Curator and Blogger

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Written By

Related Posts

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated